Search This Blog

Monday, 29 June 2015

Clinical Pharmacologists from Switzerland and Finland at the EACPT Madrid Congress

The 12th biennial Congress of the European Association for Clinical Pharmacology and Therapeutics (http://eacpt.eu) was held in Madrid from 27th to 30th June 2015. Over 500 abstractswere accepted from 66 countries and form all 5 continents for presentation as e-posters and oral presentations. The 54 oral presentations were eligible for awards for the best talk. 

Roseline Ing Lorenzini, Maria Paile-Hyuvarinen, Helina Kahmamarija, Marija Bosilkovska and Flavia Storelli


Watch the video with Clinical Pharmacologists in training from Switzerland and Finland discussing their interests at the EACPT Madrid Congress.



Flavia Storelli obtained a Master’s Degree (MSc) in Pharmacy in 2013 from the University of Geneva. Since 2014, she has been a PhD candidate in Clinical Pharmacology at Geneva University Hospitals. Her main interest is the in vitro study of drug-drug interactions regarding CYP450 enzymes and hepatic transporters in the HepaRG cell line.
She studies in the Division of Clinical Pharmacology and Toxicology at Geneva University Hospitals

Dr Roseline-Kuntheavy Ing Lorenzini has been since 2014 non-MD clinical pharmacologist. She graduated as a pharmacist in 2003, then did a MAS (Master of Advanced Studies) in hospital pharmacy from 2004 to 2006, followed by a PhD thesis in clinical pharmacology which ended in 2011 on the use of paracetamol and NSAIDs in combination.  She has worked since 2011 as a pharmacist project manager in the Division of Clinical Pharmacology at the University of Geneva Hospitals. Her interests are: TDM, pharmacogenetics, and drug-drug interactio,ns more particularly in anti-retroviral therapies.

Helinä Kahma graduated as a pharmacist (MSc Pharm) in 2014 from the University of Helsinki and started her PhD in clinical pharmacology in the Faculty of Medicine at the University of Helsinki in January this year. Her research topic is drug-drug interactions based on mechanism-based inhibition of CYP450 enzymes. Her main interest is in enzyme- and transporter-based DDIs.
 

No comments:

Post a Comment